ReP USP - Resultado da busca

Artigo de periodico
Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial (2022)
Baptista, Marcella Vassao de Almeida; Silva, Lais Teodoro da; Samer, Sadia; Oshiro, Telma Miyuki; Shytaj, Iart Luca; Giron, Leila B.; Pena, Nathalia Mantovani; Cruz, Nicolly; Cunha Neto, Edecio ; Duarte, Alberto José da Silva
Source: Aids research and therapy. Unidade: FM
Subjects: HIV, IMUNOGENICIDADE DA VACINA, CÉLULAS DENDRÍTICAS, SÍNDROME DE IMUNODEFICIÊNCIA ADQUIRIDA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BAPTISTA, Marcella Vassao de Almeida et al. Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial. Aids research and therapy, v. 19, n. 1, 2022Tradução . . Disponível em: https://doi.org/10.1186/s12981-021-00426-z. Acesso em: 07 nov. 2024.
APA
Baptista, M. V. de A., Silva, L. T. da, Samer, S., Oshiro, T. M., Shytaj, I. L., Giron, L. B., et al. (2022). Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial. Aids research and therapy, 19( 1). doi:10.1186/s12981-021-00426-z
NLM
Baptista MV de A, Silva LT da, Samer S, Oshiro TM, Shytaj IL, Giron LB, Pena NM, Cruz N, Cunha Neto E, Duarte AJ da S. Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial [Internet]. Aids research and therapy. 2022 ; 19( 1):[citado 2024 nov. 07 ] Available from: https://doi.org/10.1186/s12981-021-00426-z
Vancouver
Baptista MV de A, Silva LT da, Samer S, Oshiro TM, Shytaj IL, Giron LB, Pena NM, Cruz N, Cunha Neto E, Duarte AJ da S. Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial [Internet]. Aids research and therapy. 2022 ; 19( 1):[citado 2024 nov. 07 ] Available from: https://doi.org/10.1186/s12981-021-00426-z
Artigo de periodico-carta/editorial
Patient with agammaglobulinemia produces anti-SARS-CoV-2 reactive T-cells after CoronaVac vaccine [Editorial] (2022)
Oshiro, Telma Miyuki; Silva, Lais Teodoro da; Ortega, Marina Mazzilli; Perazzio, Sandro Felix; Duarte, Alberto José da Silva; Sampaio, Magda Maria Sales Carneiro
Source: Clinics. Unidade: FM
Subjects: VACINAÇÃO, VACINAS VIRAIS, COVID-19, EVENTO ADVERSO A MEDICAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OSHIRO, Telma Miyuki et al. Patient with agammaglobulinemia produces anti-SARS-CoV-2 reactive T-cells after CoronaVac vaccine [Editorial]. Clinics. Madrid: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.clinsp.2022.100007. Acesso em: 07 nov. 2024. , 2022
APA
Oshiro, T. M., Silva, L. T. da, Ortega, M. M., Perazzio, S. F., Duarte, A. J. da S., & Sampaio, M. M. S. C. (2022). Patient with agammaglobulinemia produces anti-SARS-CoV-2 reactive T-cells after CoronaVac vaccine [Editorial]. Clinics. Madrid: Faculdade de Medicina, Universidade de São Paulo. doi:10.1016/j.clinsp.2022.100007
NLM
Oshiro TM, Silva LT da, Ortega MM, Perazzio SF, Duarte AJ da S, Sampaio MMSC. Patient with agammaglobulinemia produces anti-SARS-CoV-2 reactive T-cells after CoronaVac vaccine [Editorial] [Internet]. Clinics. 2022 ; 77[citado 2024 nov. 07 ] Available from: https://doi.org/10.1016/j.clinsp.2022.100007
Vancouver
Oshiro TM, Silva LT da, Ortega MM, Perazzio SF, Duarte AJ da S, Sampaio MMSC. Patient with agammaglobulinemia produces anti-SARS-CoV-2 reactive T-cells after CoronaVac vaccine [Editorial] [Internet]. Clinics. 2022 ; 77[citado 2024 nov. 07 ] Available from: https://doi.org/10.1016/j.clinsp.2022.100007
Artigo de periodico
Characterization of monocyte-derived dendritic cells used in immunotherapy for HIV-1-infected individuals (2018)
Silva, Lais Teodoro da; Duarte, Alberto Jose da Silva; Silva, Wanessa Cardoso da; Almeida, Alexandre de; Reis, Denise da Silva; Santllo, Bruna Tereso; Rigato, Paula Ordonhez; Oshiro, Telma Miyuki
Source: Immunotherapy. Unidade: FM
Subjects: ANTIRRETROVIRAIS, IMUNIZAÇÃO, RNA, IMUNOTERAPIA, HIV, CÉLULAS DENDRÍTICAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Lais Teodoro da et al. Characterization of monocyte-derived dendritic cells used in immunotherapy for HIV-1-infected individuals. Immunotherapy, v. 10, n. 10, p. 871-885, 2018Tradução . . Disponível em: https://doi.org/10.2217/imt-2017-0165. Acesso em: 07 nov. 2024.
APA
Silva, L. T. da, Duarte, A. J. da S., Silva, W. C. da, Almeida, A. de, Reis, D. da S., Santllo, B. T., et al. (2018). Characterization of monocyte-derived dendritic cells used in immunotherapy for HIV-1-infected individuals. Immunotherapy, 10( 10), 871-885. doi:10.2217/imt-2017-0165
NLM
Silva LT da, Duarte AJ da S, Silva WC da, Almeida A de, Reis D da S, Santllo BT, Rigato PO, Oshiro TM. Characterization of monocyte-derived dendritic cells used in immunotherapy for HIV-1-infected individuals [Internet]. Immunotherapy. 2018 ; 10( 10): 871-885.[citado 2024 nov. 07 ] Available from: https://doi.org/10.2217/imt-2017-0165
Vancouver
Silva LT da, Duarte AJ da S, Silva WC da, Almeida A de, Reis D da S, Santllo BT, Rigato PO, Oshiro TM. Characterization of monocyte-derived dendritic cells used in immunotherapy for HIV-1-infected individuals [Internet]. Immunotherapy. 2018 ; 10( 10): 871-885.[citado 2024 nov. 07 ] Available from: https://doi.org/10.2217/imt-2017-0165
Artigo de periodico-resenha
Using Dendritic Cell-Based Immunotherapy to Treat HIV: How Can This Strategy be Improved? (2018)
Silva, Lais Teodoro da; Santillo, Bruna Tereso; Almeida, Alexandre de; Duarte, Alberto Jose da Silva; Oshiro, Telma Miyuki
Source: Frontiers in immunology. Unidade: FM
Subjects: IMUNOTERAPIA, CÉLULAS DENDRÍTICAS, INFECÇÕES POR HIV
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Lais Teodoro da et al. Using Dendritic Cell-Based Immunotherapy to Treat HIV: How Can This Strategy be Improved?. Frontiers in immunology. Lausanne: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.3389/fimmu.2018.02993. Acesso em: 07 nov. 2024. , 2018
APA
Silva, L. T. da, Santillo, B. T., Almeida, A. de, Duarte, A. J. da S., & Oshiro, T. M. (2018). Using Dendritic Cell-Based Immunotherapy to Treat HIV: How Can This Strategy be Improved? Frontiers in immunology. Lausanne: Faculdade de Medicina, Universidade de São Paulo. doi:10.3389/fimmu.2018.02993
NLM
Silva LT da, Santillo BT, Almeida A de, Duarte AJ da S, Oshiro TM. Using Dendritic Cell-Based Immunotherapy to Treat HIV: How Can This Strategy be Improved? [Internet]. Frontiers in immunology. 2018 ; 9[citado 2024 nov. 07 ] Available from: https://doi.org/10.3389/fimmu.2018.02993
Vancouver
Silva LT da, Santillo BT, Almeida A de, Duarte AJ da S, Oshiro TM. Using Dendritic Cell-Based Immunotherapy to Treat HIV: How Can This Strategy be Improved? [Internet]. Frontiers in immunology. 2018 ; 9[citado 2024 nov. 07 ] Available from: https://doi.org/10.3389/fimmu.2018.02993
Trabalho de evento-resumo periodico
Type-1 and type-2 polarized dendritic cells differ on complement protein expression (2014)
Palma, Mariana de Lucena; Nascimento, Eduardo José Moura do; Mailliard, Robbie; Oshiro, Telma Miyuki; Duarte, Alberto José da Silva; Marques, Ernesto Torres de Azevedo
Source: Molecular Immunology. Conference titles: International Complement Workshop. Unidade: FM
Subjects: PROTEÍNAS, CITOCINAS, CÉLULAS DENDRÍTICAS, SISTEMA IMUNE, LINFÓCITOS T
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PALMA, Mariana de Lucena et al. Type-1 and type-2 polarized dendritic cells differ on complement protein expression. Molecular Immunology. New York: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://ac.els-cdn.com/S0161589014001801/1-s2.0-S0161589014001801-main.pdf?_tid=c787756c-65ba-11e4-8413-00000aacb362&acdnat=1415281541_92464eb60fd47505ea966b230703cf47. Acesso em: 07 nov. 2024. , 2014
APA
Palma, M. de L., Nascimento, E. J. M. do, Mailliard, R., Oshiro, T. M., Duarte, A. J. da S., & Marques, E. T. de A. (2014). Type-1 and type-2 polarized dendritic cells differ on complement protein expression. Molecular Immunology. New York: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://ac.els-cdn.com/S0161589014001801/1-s2.0-S0161589014001801-main.pdf?_tid=c787756c-65ba-11e4-8413-00000aacb362&acdnat=1415281541_92464eb60fd47505ea966b230703cf47
NLM
Palma M de L, Nascimento EJM do, Mailliard R, Oshiro TM, Duarte AJ da S, Marques ET de A. Type-1 and type-2 polarized dendritic cells differ on complement protein expression [Internet]. Molecular Immunology. 2014 ; 61( 2): 285.[citado 2024 nov. 07 ] Available from: http://ac.els-cdn.com/S0161589014001801/1-s2.0-S0161589014001801-main.pdf?_tid=c787756c-65ba-11e4-8413-00000aacb362&acdnat=1415281541_92464eb60fd47505ea966b230703cf47
Vancouver
Palma M de L, Nascimento EJM do, Mailliard R, Oshiro TM, Duarte AJ da S, Marques ET de A. Type-1 and type-2 polarized dendritic cells differ on complement protein expression [Internet]. Molecular Immunology. 2014 ; 61( 2): 285.[citado 2024 nov. 07 ] Available from: http://ac.els-cdn.com/S0161589014001801/1-s2.0-S0161589014001801-main.pdf?_tid=c787756c-65ba-11e4-8413-00000aacb362&acdnat=1415281541_92464eb60fd47505ea966b230703cf47
Artigo de periodico
Autologous and allogenic systems of HIV expansion: what is the better choice for clinical application in therapeutic vaccine? (2013)
Silva, Lais Teodoro da; Pontillo, Alessandra ; Silva, Wanessa Cardoso da; Almeida, Alexandre de; Duarte, Alberto José da Silva; Oshiro, Telma Miyuki
Source: Immunotherapy. Unidades: ICB, FM
Assunto: IMUNOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Lais Teodoro da et al. Autologous and allogenic systems of HIV expansion: what is the better choice for clinical application in therapeutic vaccine?. Immunotherapy, v. 5, n. 12, p. 1305-1311, 2013Tradução . . Disponível em: https://doi.org/10.2217/imt.13.136. Acesso em: 07 nov. 2024.
APA
Silva, L. T. da, Pontillo, A., Silva, W. C. da, Almeida, A. de, Duarte, A. J. da S., & Oshiro, T. M. (2013). Autologous and allogenic systems of HIV expansion: what is the better choice for clinical application in therapeutic vaccine? Immunotherapy, 5( 12), 1305-1311. doi:10.2217/imt.13.136
NLM
Silva LT da, Pontillo A, Silva WC da, Almeida A de, Duarte AJ da S, Oshiro TM. Autologous and allogenic systems of HIV expansion: what is the better choice for clinical application in therapeutic vaccine? [Internet]. Immunotherapy. 2013 ; 5( 12): 1305-1311.[citado 2024 nov. 07 ] Available from: https://doi.org/10.2217/imt.13.136
Vancouver
Silva LT da, Pontillo A, Silva WC da, Almeida A de, Duarte AJ da S, Oshiro TM. Autologous and allogenic systems of HIV expansion: what is the better choice for clinical application in therapeutic vaccine? [Internet]. Immunotherapy. 2013 ; 5( 12): 1305-1311.[citado 2024 nov. 07 ] Available from: https://doi.org/10.2217/imt.13.136

USP Schools

ReP

Filtros

Authors

Subjects

Funding Agencies

Indexado em